Concenter BioPharma | Focused on People & Therapies

Sugar cubes & pills to prevent type 2.jpg

FOCUSED ON PEOPLE & THERAPIES

Concenter Biopharma receives approval from

ISRAELI Ministry of Health for conducting clinical trial

using its newly developed ORAL dose drug on

Type 2 Diabetes patients (01/2024)

Developing Novel, First in Class Drugs, Treating and Preventing

Type 2 Diabetes, Based on a Core-Technology-Platform.

Short Summary

Pipeline IND in process

Type 2 Diabetes Drug

Professor Chevion and co-inventors developed a family of non-steroidal chemical complexes, made of components approved for clinical use.

These New Chemical Entities constitute a protected PLATFORM of DRUGS, with proven efficacy and complete safety, for treatments of multiple indications. Concenter BioPharma is developing and commercializing the drug which treats and prevents Type 2 Diabetes.

The drug has 3 synergistic Mechanisms of Action, extensively tested in animal models of human diseases

(and anecdotal human cases).

Prof. DeFronzo presentation audio at the 17th World Congress

on Insulin Resistance. Diabetes & Cardiovascular Disease [2019]

Insulin Resistance All You Wanted to KnowProf. DeFronzo

About

ABOUT US & VISION

VISION

Becoming a global specialty biopharmaceutical company by advancing a pipeline of products that demonstrate vast potential for treating TYPE 2 DIABETES.

ABOUT

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications.

Our PLATFORM is the result of extensive investigation of animal models of human diseases.

MEMBERS OF OUR PLATFORM ACT AS:

Potent anti-inflammatory agents, Strong iron-chelating agents, and Anti-biotic agents.

MORE ABOUT US

strategy

STRATEGY OVERVIEW

To rapidly advance from laboratory experiments to clinical trials in Type 2 Diabetes based on "shortcut"

regulatory routes, that enable a shorter time from the lab to treating patients.

Our initial focus is on a leveraging Expedited Pathway programs.

Our focus leverages the global demand-creating patient population of about 570 million people with Diabetes.

Our drug for treating Type 2 Diabetes (Pill) – extensively demonstrated as effective in both prevention and treatment of T2 Diabetes – by Restoring Insulin Resistance to Normal Levels!

Markedly inhibiting the appearance and the degree of hyperglycemia; lowering LDL; lowering body weight; reduction of cataract formation and diabetes-induced retinopathy.